<DOC>
	<DOCNO>NCT00089271</DOCNO>
	<brief_summary>This phase I trial study side effect best dose 17-DMAG treating patient metastatic unresectable solid tumor lymphomas . Drugs use chemotherapy , 17-DMAG , work different way stop cancer cell divide stop growing die</brief_summary>
	<brief_title>17-DMAG Treating Patients With Metastatic Unresectable Solid Tumors Lymphomas</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose 17-dimethylaminoethylamino-17-demethoxygeldanamycin ( 17-DMAG ) patient metastatic unresectable solid tumor lymphomas . II . Determine safety toxicity drug patient . III . Determine pharmacokinetics pharmacodynamics drug patient . IV . Determine recommend phase II dose drug future study . SECONDARY OBJECTIVES : I . Determine tumor response patient treated drug . OUTLINE : This dose-escalation , multicenter study . Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin ( 17-DMAG ) IV 1-6 hour day 1-3 1-5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 1-2 patient receive accelerate escalating dos 17-DMAG least 1 2 patient experience dose-limiting toxicity ( DLT ) . Cohorts expand 3-6 patient receive escalate dos ( standard manner ) 17-DMAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience DLT . Patients follow 4 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<criteria>Histologically confirm solid tumor lymphoma Metastatic unresectable disease Standard curative palliative measure exist longer effective No known brain metastasis Performance status ECOG 02 Performance status Karnofsky 60100 % More 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL ALT AST ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ normal Creatinine ≤ 1.25 time ULN Creatinine clearance ≥ 60 mL/min QTc &lt; 450 msec male patient ( 470 msec female patient ) LVEF &gt; 40 % MUGA No history serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No myocardial infarction active ischemic heart disease within past year No New York Heart Association class III IV congestive heart failure No poorly control angina No uncontrolled dysrhythmia require medication No leave bundle branch block No history congenital long QT syndrome No significant cardiac disease Pulse oximetry rest exercise &gt; 88 % No symptomatic pulmonary disease ( e.g. , chronic obstructive restrictive pulmonary disease , etc . ) follow allow : Pulmonary disease require medication History dyspnea , dyspnea exertion , paroxysmal nocturnal dyspnea Patients meet Medicare criterion home oxygen oxygen Not pregnant nursing Negative pregnancy test Fertile patient must use effective double barrier contraception 1 week , , least 2 week study participation No uncontrolled illness No active ongoing infection No history allergic reaction attribute compound similar chemical biological composition 17dimethylaminoethylamino17demethoxygeldanamycin ( 17DMAG ) No psychiatric illness social situation would preclude study compliance No concurrent routine colonystimulating factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Concurrent hormonal therapy allow At least 4 week since prior radiotherapy recover No prior radiation include heart field ( e.g. , mantle ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer agent therapies No concurrent medication would prolong QTc interval No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>